mRNA Modification |
 |
Synthetic messenger RNA (mRNA) can be used to deliver exogenous genetic information inside cells that is converted by the cellular translational machinery into the encoded protein which subsequently induces a cellular response depending on its biological function.
Therapeutic protein encoding mRNAs have most recently gained increasing attention as versatile protein delivery molecules in non-viral gene therapy mostly due to their superior safety profile compared to plasmid DNA-based approaches (inability to integrate into the host genome)[1]. In addition, high-purity mRNA is easily synthesized even large scales by phage RNA polymerase-mediated in vitro transcription[2,3].
Their application however, was so far been hampered by the limited stability and strong immunogenicity of in vitro transcribed mRNAs subsequently leading to increased expression rates of the respective protein.
Enzymatic incorporation of a set several nucleotide analogs (single or combined) during the transcription process markedly improves the pharmacokinetic properties of in vitro transcribed mRNA both in terms of stability (increased nuclease resistance) and decreased immunogenicity (Fig. 1)[4-8].
Find more Cap analogs in the 5'-Capping section!
Therapeutic protein encoding mRNAs have most recently gained increasing attention as versatile protein delivery molecules in non-viral gene therapy mostly due to their superior safety profile compared to plasmid DNA-based approaches (inability to integrate into the host genome)[1]. In addition, high-purity mRNA is easily synthesized even large scales by phage RNA polymerase-mediated in vitro transcription[2,3].
Their application however, was so far been hampered by the limited stability and strong immunogenicity of in vitro transcribed mRNAs subsequently leading to increased expression rates of the respective protein.
Enzymatic incorporation of a set several nucleotide analogs (single or combined) during the transcription process markedly improves the pharmacokinetic properties of in vitro transcribed mRNA both in terms of stability (increased nuclease resistance) and decreased immunogenicity (Fig. 1)[4-8].
Find more Cap analogs in the 5'-Capping section!
Figure 1: Pharmacokinetic properties of synthetic mRNA are improved by nucleotide analog incorporation during in vitro RNA synthesis. ARCA: "anti-reverse" cap analog, m5CTP = 5'-methyl-cytidine triphosphate, m6ATP=N6-methyl-adenosine-5'-triphosphate, s2UTP = 2-thio-uridine triphosphate, Ѱ = pseudouridine triphosphate.
For bulk inquiries please contact us at nucleotides@jenabioscience.com
| |||||||||||||||||||
| |||||||||||||||||||
Datasheet
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
|
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
Информация представлена исключительно в ознакомительных целях и ни при каких условиях не является публичной офертой
